Abstract:PurposeTo report a case of bilateral bullous exudative retinal detachment in central serous chorioretinopathy (CSC) which was attached by vitrectomy and internal drainage of the subretinal fluid.MethodsA 47-year-old man affected by bilateral atypical CSC with a bullous retinal detachment with subretinal exudate. A fluorescein angiogram (FAG) showed multiple points of leakage and staining of subretinal fibrosis. A tentative diagnosis of Vogt-Koyanagi-Harada (VKH) syndrome was made and the patient was treated wi… Show more
“…Various treatments for CSC, including the use of medication [12,13,14,15], transpupillary thermotherapy [16,17] and surgery [18], have been studied. However, no optimal treatment for CSC has been determined.…”
Background: Our purpose was to report the results of 1-year follow-up examinations after intravitreal bevacizumab injection for the treatment of chronic central serous chorioretinopathy (CSC). Methods: Five eyes in 5 patients with chronic CSC were intravitreally injected with 1.25 mg/0.05 ml of bevacizumab. The need for retreatment was evaluated if spectral-domain optical coherence tomography showed the presence of subretinal fluid at the time of a 1-month follow-up examination. Best-corrected visual acuity and central foveal thickness were compared between baseline and 1 year after the first injection. Results: The mean logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity improved from 0.23 ± 0.46 to 0.17 ± 0.47 and the mean central foveal thickness significantly decreased from 323 ± 98 µm to 171 ± 63 µm (p < 0.05). Conclusion: The intravitreal injection of bevacizumab is well tolerated in maintaining vision and reducing serous retinal detachment in patients with chronic CSC, as evaluated at a 1-year follow-up examination.
“…Various treatments for CSC, including the use of medication [12,13,14,15], transpupillary thermotherapy [16,17] and surgery [18], have been studied. However, no optimal treatment for CSC has been determined.…”
Background: Our purpose was to report the results of 1-year follow-up examinations after intravitreal bevacizumab injection for the treatment of chronic central serous chorioretinopathy (CSC). Methods: Five eyes in 5 patients with chronic CSC were intravitreally injected with 1.25 mg/0.05 ml of bevacizumab. The need for retreatment was evaluated if spectral-domain optical coherence tomography showed the presence of subretinal fluid at the time of a 1-month follow-up examination. Best-corrected visual acuity and central foveal thickness were compared between baseline and 1 year after the first injection. Results: The mean logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity improved from 0.23 ± 0.46 to 0.17 ± 0.47 and the mean central foveal thickness significantly decreased from 323 ± 98 µm to 171 ± 63 µm (p < 0.05). Conclusion: The intravitreal injection of bevacizumab is well tolerated in maintaining vision and reducing serous retinal detachment in patients with chronic CSC, as evaluated at a 1-year follow-up examination.
“…We did not note any capillary non‐perfusion on fluorescein angiography in the posterior pole of the left eye, which again supports the diagnosis of central serous chorioretinopathy and rules out the possibility of other retinal vasculopathies, like old retinal vascular occlusions or retinal vasculitis. Such abnormal arborising peripapillary vessels have not been reported before in central serous chorioretinopathy probably because inferior retinal detachment in central serous chorioretinopathy is a rare manifestation of this disease …”
“…The findings of bullous CSCR may be confused with uveal effusion, metastatic carcinoma or lymphoma, rhegmatogenous retinal detachment, and diseases that cause inflammation such as VKH disease, multifocal choroiditis, and sympathetic ophthalmia, and misdiagnosis results in unnecessary tests and treatments. 5 , 9 Kang et al 10 observed progression of bullous detachment in a 47-year-old male patient who was treated with systemic corticosteroids for a prediagnosis of VKH; they subsequently discontinued the medication and successfully treated the patient with vitrectomy and internal subretinal fluid drainage. Gao and Li 11 reported a patient with a previous history of CSCR whose disease converted to the bullous form after being treated with systemic methylprednisolone due to misdiagnosis of VKH.…”
Bullous central serous chorioretinopathy (CSCR) is a rare variant of CSCR characterized by severe serous retinal detachment which especially involves the inferior quadrants. Corticosteroid therapy administered for systemic or ocular misdiagnoses may induce and exacerbate CSCR. The purpose of this study was to report diagnosis and treatment results of an unusual case of bullous CSCR induced by systemic and periocular corticosteroid therapy received at another medical center due to a misdiagnosis of Vogt-Koyanagi-Harada disease.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.